Literature DB >> 30970390

Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries.

Jessica Duby1, Zohra S Lassi, Zulfiqar A Bhutta.   

Abstract

BACKGROUND: The recommended management for neonates with a possible serious bacterial infection (PSBI) is hospitalisation and treatment with intravenous antibiotics, such as ampicillin plus gentamicin. However, hospitalisation is often not feasible for neonates in low- and middle-income countries (LMICs). Therefore, alternative options for the management of neonatal PSBI in LMICs needs to be evaluated.
OBJECTIVES: To assess the effects of community-based antibiotics for neonatal PSBI in LMICs on neonatal mortality and to assess whether the effects of community-based antibiotics for neonatal PSBI differ according to the antibiotic regimen administered. SEARCH
METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 3), MEDLINE via PubMed (1966 to 16 April 2018), Embase (1980 to 16 April 2018), and CINAHL (1982 to 16 April 2018). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi-randomised trials. SELECTION CRITERIA: We included randomised, quasi-randomised and cluster-randomised trials. For the first comparison, we included trials that compared antibiotics which were initiated and completed in the community to the standard hospital referral for neonatal PSBI in LMICs. For the second comparison, we included trials that compared simplified antibiotic regimens which relied more on oral antibiotics than intravenous antibiotics to the standard regimen of seven to 10 days of injectable penicillin/ampicillin with an injectable aminoglycoside delivered in the community to treat neonatal PSBI. DATA COLLECTION AND ANALYSIS: We extracted data using the standard methods of the Cochrane Neonatal Group. The primary outcomes were all-cause neonatal mortality and sepsis-specific neonatal mortality. We used the GRADE approach to assess the quality of evidence. MAIN
RESULTS: For the first comparison, five studies met the inclusion criteria. Community-based antibiotic delivery for neonatal PSBI reduced neonatal mortality when compared to hospital referral only (typical risk ratio (RR) 0.82, 95% confidence interval (CI) 0.68 to 0.99; 5 studies, n = 125,134; low-quality evidence). There was, however, a high level of statistical heterogeneity (I² = 87%) likely, due to the heterogenous nature of the study settings as well as the fact that four of the studies provided various co-interventions in conjunction with community-based antibiotics. Community-based antibiotic delivery for neonatal PSBI showed a possible effect on reducing sepsis-specific neonatal mortality (typical RR 0.78, 95% CI 0.60 to 1.00; 2 studies, n = 40,233; low-quality evidence).For the second comparison, five studies met the inclusion criteria. Using a simplified antibiotic approach resulted in similar rates of neonatal mortality when compared to the standard regimen of seven days of injectable procaine benzylpenicillin and injectable procaine benzylpenicillin and injectable gentamicin delivered in community-settings for neonatal PSBI (typical RR 0.81, 95% CI 0.44 to 1.50; 3 studies, n = 3476; moderate-quality evidence). In subgroup analysis, the simplified antibiotic regimen of seven days of oral amoxicillin and injectable gentamicin showed no difference in neonatal mortality (typical RR 0.84, 95% CI 0.47 to 1.51; 3 studies, n = 2001; moderate-quality evidence). Two days of injectable benzylpenicillin and injectable gentamicin followed by five days of oral amoxicillin showed no difference in neonatal mortality (typical RR 0.88, 95% CI 0.29 to 2.65; 3 studies, n = 2036; low-quality evidence). Two days of injectable gentamicin and oral amoxicillin followed by five days of oral amoxicillin showed no difference in neonatal mortality (RR 0.67, 95% CI 0.24 to 1.85; 1 study, n = 893; moderate-quality evidence). For fast breathing alone, seven days of oral amoxicillin resulted in no difference in neonatal mortality (RR 0.99, 95% CI 0.20 to 4.91; 1 study, n = 1406; low-quality evidence). None of the studies in the second comparison reported the effect of a simplified antibiotic regimen on sepsis-specific neonatal mortality. AUTHORS'
CONCLUSIONS: Low-quality data demonstrated that community-based antibiotics reduced neonatal mortality when compared to the standard hospital referral for neonatal PSBI in resource-limited settings. The use of co-interventions, however, prevent disentanglement of the contribution from community-based antibiotics. Moderate-quality evidence showed that simplified, community-based treatment of PSBI using regimens which rely on the combination of oral and injectable antibiotics did not result in increased neonatal mortality when compared to the standard treatment of using only injectable antibiotics. Overall, the evidence suggests that simplified, community-based antibiotics may be efficacious to treat neonatal PSBI when hospitalisation is not feasible. However, implementation research is recommended to study the effectiveness and scale-up of simplified, community-based antibiotics in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30970390      PMCID: PMC6458055          DOI: 10.1002/14651858.CD007646.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  57 in total

Review 1.  Time for a neonatal-specific consensus definition for sepsis.

Authors:  James L Wynn; Hector R Wong; Thomas P Shanley; Matthew J Bizzarro; Lisa Saiman; Richard A Polin
Journal:  Pediatr Crit Care Med       Date:  2014-07       Impact factor: 3.624

2.  Volume of blood required to detect common neonatal pathogens.

Authors:  R L Schelonka; M K Chai; B A Yoder; D Hensley; R M Brockett; D P Ascher
Journal:  J Pediatr       Date:  1996-08       Impact factor: 4.406

3.  Teaching mothers to provide home treatment of malaria in Tigray, Ethiopia: a randomised trial.

Authors:  G Kidane; R H Morrow
Journal:  Lancet       Date:  2000-08-12       Impact factor: 79.321

4.  Community-based treatment of serious bacterial infections in newborns and young infants: a randomized controlled trial assessing three antibiotic regimens.

Authors:  Anita K M Zaidi; Shiyam Sundar Tikmani; Haider J Warraich; Gary L Darmstadt; Zulfiqar A Bhutta; Shazia Sultana; Durrane Thaver
Journal:  Pediatr Infect Dis J       Date:  2012-07       Impact factor: 2.129

5.  Effect of community-based newborn-care intervention package implemented through two service-delivery strategies in Sylhet district, Bangladesh: a cluster-randomised controlled trial.

Authors:  Abdullah H Baqui; Shams El-Arifeen; Gary L Darmstadt; Saifuddin Ahmed; Emma K Williams; Habibur R Seraji; Ishtiaq Mannan; Syed M Rahman; Rasheduzzaman Shah; Samir K Saha; Uzma Syed; Peter J Winch; Amnesty Lefevre; Mathuram Santosham; Robert E Black
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

6.  Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study.

Authors:  Christopher J Gill; Grace Phiri-Mazala; Nicholas G Guerina; Joshua Kasimba; Charity Mulenga; William B MacLeod; Nelson Waitolo; Anna B Knapp; Mark Mirochnick; Arthur Mazimba; Matthew P Fox; Lora Sabin; Philip Seidenberg; Jonathon L Simon; Davidson H Hamer
Journal:  BMJ       Date:  2011-02-03

7.  Community health workers can identify and manage possible infections in neonates and young infants: MINI--a model from Nepal.

Authors:  Sudhir Khanal; Jaganath Sharma; Vijay Singh GC; Penny Dawson; Robin Houston; Neena Khadka; Bhanu Yengden
Journal:  J Health Popul Nutr       Date:  2011-06       Impact factor: 2.000

8.  Expanding the population coverage of evidence-based interventions with community health workers to save the lives of mothers and children: an analysis of potential global impact using the Lives Saved Tool (LiST).

Authors:  Victoria B Chou; Ingrid K Friberg; Mervyn Christian; Neff Walker; Henry B Perry
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

9.  Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis.

Authors:  Li Liu; Shefali Oza; Daniel Hogan; Jamie Perin; Igor Rudan; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black
Journal:  Lancet       Date:  2014-09-30       Impact factor: 79.321

10.  Simplified regimens for management of neonates and young infants with severe infection when hospital admission is not possible: study protocol for a randomized, open-label equivalence trial.

Authors: 
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

View more
  3 in total

1.  Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries.

Authors:  Jessica Duby; Zohra S Lassi; Zulfiqar A Bhutta
Journal:  Cochrane Database Syst Rev       Date:  2019-04-11

2.  Feasibility of implementation of simplified management of young infants with possible serious bacterial infection when referral is not feasible in tribal areas of Pune district, Maharashtra, India.

Authors:  Sudipto Roy; Rutuja Patil; Aditi Apte; Kavita Thibe; Arun Dhongade; Bhagawan Pawar; Yasir Bin Nisar; Samira Aboubaker; Shamim Ahmad Qazi; Rajiv Bahl; Archana Patil; Sanjay Juvekar; Ashish Bavdekar
Journal:  PLoS One       Date:  2020-08-24       Impact factor: 3.240

3.  Caregiver acceptability of the guidelines for managing young infants with possible serious bacterial infections (PSBI) in primary care facilities in rural Bangladesh.

Authors:  Jennifer A Applegate; Salahuddin Ahmed; Meagan Harrison; Jennifer Callaghan-Koru; Mahfuza Mousumi; Nazma Begum; Mamun Ibne Moin; Taufique Joarder; Sabbir Ahmed; Joby George; Dipak K Mitra; Asm Nawshad Uddin Ahmed; Mohammod Shahidullah; Abdullah H Baqui
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.